Ignite Creation Date:
2025-12-24 @ 8:03 PM
Ignite Modification Date:
2026-03-06 @ 10:10 PM
Study NCT ID:
NCT02069704
Status:
COMPLETED
Last Update Posted:
2019-07-23
First Post:
2014-02-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
Sponsor:
mAbxience Research S.L.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
BEVZ92-A-01-13
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None